Drug
Basimglurant clinical trials
Also written RO4917523.
- studies test it
- 14
- open now
- 0
- in phase 3
- 1
- first study started
- 2009
How studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2012 (4)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 4 |
| 2013 | 2 |
| 2015 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 6
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 0
Hoffmann-La Roche (13) · Noema Pharma AG (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses basimglurant is read from its arms, and is right about nine times in ten.
Testing it · 14
- An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.Active, not recruitingPhase 2/3Noema Pharma AGNCT05217628Written as Basimglurant
- A Study of RO4917523 in Patients With Treatment Resistant DepressionCompletedPhase 2Hoffmann-La RocheNCT00809562Written as RO4917523
- MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant TherapyCompletedPhase 2Hoffmann-La RocheNCT01437657Written as RO4917523 0.5 mg
- A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian SubjectsCompletedPhase 1Hoffmann-La RocheNCT01368926Written as RO4917523
- A Study of the Effect of Carbamazepine on the Pharmacokinetics of RO4917523 in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01629368Written as RO4917523
- A Study of the Effect of Fluvoxamine on the Pharmacokinetics of RO4917523 in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01665404Written as RO4917523
- A Study With RO4917523 in Patients With Fragile X SyndromeCompletedPhase 2Hoffmann-La RocheNCT01015430Written as RO4917523
- A Human Proof of Concept Study for [11C]-RO5011232 as Radiotracer and Study of the Binding of RO4917523 to Human mGlu5 Brain Receptor at Steady-State in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01483469Written as RO4917523
- A Study of The Excretion Balance, Pharmacokinetics and Metabolism of A Single Oral Dose of [14C]-Labeled RO4917523 in Healthy Male VolunteersCompletedPhase 1Hoffmann-La RocheNCT01592890Written as RO4917523
- A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)CompletedPhase 1Hoffmann-La RocheNCT02433093Written as Basimglurant
- A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01045083Written as RO4917523
- A Study of RO4917523 in Pediatric Patients With Fragile X SyndromeCompletedPhase 2Hoffmann-La RocheNCT01750957Written as RO4917523
- A Study of RO4917523 in Patients With Fragile X SyndromeCompletedPhase 2Hoffmann-La RocheNCT01517698Written as RO4917523 0.5 mg
- A Study of Three Modified-Release Formulations of RO4917523 in Healthy VolunteersCompletedPhase 1Hoffmann-La RocheNCT01873508Written as RO4917523
Codes
What other systems call basimglurant · ClinicalTrials.gg INT000201
- UNII (FDA) 3110E3AO8SBASIMGLURANTConfirmed FDA, Wikidata
- Wikidata Q18209947basimglurantConfirmed FDA, Wikidata
- NCI Thesaurus C166619BasimglurantOne source FDA
- DrugBank DB11833One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3110E3AO8S | BASIMGLURANT | Confirmed FDA, Wikidata |
| Wikidata | Q18209947 | basimglurant | Confirmed FDA, Wikidata |
| NCI Thesaurus | C166619 | Basimglurant | One source FDA |
| DrugBank | DB11833 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.